<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212458</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.03</org_study_id>
    <nct_id>NCT01212458</nct_id>
  </id_info>
  <brief_title>Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Untersuchungen über die Wirkmechanismen von Antiepileptika haben gezeigt, dass durch eine
      Blockierung von spannungsabhängigen Natrium-Kanälen im Nervensystem die Schmerzübertragung
      moduliert werden kann. Verschiedene Antiepileptika werden in der chronischen Schmerztherapie
      schon lange angewendet (z.B. Oxcarbazepinum, Trileptal ® bei Trigeminusneuralgie oder
      diabetischer Polyneuropathie).

      In unserer Untersuchung wollen wir zwei in der Schweiz zugelassene Antiepileptika bezüglich
      ihrer Wirkung auf das Schmerzempfinden untersuchen. Eines dieser Medikamente, Trileptal®
      (Wirkstoff: Oxcarbazepinum), wird schon häufig bei chronischen Schmerzzuständen eingesetzt.
      Das zweite Medikament, Inovelon® (Wirkstoff: Rufinamid) ist seit mehr als einem Jahr in der
      Schweiz zugelassen und wird klinisch vor allem in der Behandlung von besonderen
      Epilepsieformen im Kindesalter eingesetzt. Wir erwarten, dass auch nach Gabe von Inovelon®
      die Schmerzleitung in den Nervenzellen verändert und die lokalen Schmerzreaktionen in der
      Haut vermindert werden.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rufinamid</intervention_name>
    <description>Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria: Male

          -  Age: 18-65 years

          -  Weight: 50 - 100 kg

          -  Height: 155 - 195 cm

          -  Signed and dated informed consent

        Exclusion criteria:

          -  Contraindications to the class of drugs under study

          -  Intellectually or mental impaired subjects

          -  Known hypersensitivity to class of drugs or the investigational product

          -  Drug abuse

          -  Known peripheral neuropathies

          -  Diabetes mellitus

          -  Chronic alcohol consumption

          -  Congestive heart disease

          -  Participants of other studies during study period and 30 days prior to study begin

          -  Smoker

          -  Abnormal electrocardiogram

          -  Any regular concomitant medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Institut of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Institut of Anaesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gesunde Probanden</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

